Provided by Tiger Fintech (Singapore) Pte. Ltd.

iTeos Therapeutics

7.26
-0.0900-1.22%
Volume:220.31K
Turnover:1.60M
Market Cap:277.29M
PE:-2.19
High:7.37
Open:7.31
Low:7.18
Close:7.35
Loading ...

Positive week for iTeos Therapeutics, Inc. (NASDAQ:ITOS) institutional investors who lost 38% over the past year

Simply Wall St.
·
19 Apr

iTeos Therapeutics (ITOS) Gets a Buy from Piper Sandler

TIPRANKS
·
31 Mar

iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025

GlobeNewswire
·
26 Mar

iTeos Therapeutics: Poised for Success with Anti-TIGIT Therapies Amidst Competitive Landscape

TIPRANKS
·
07 Mar

iTeos Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
07 Mar

iTeos Therapeutics price target lowered to $17 from $19 at Wells Fargo

TIPRANKS
·
06 Mar

Promising Developments and Strategic Updates Drive Buy Rating for iTeos Therapeutics

TIPRANKS
·
06 Mar

iTeos Therapeutics: Undervalued with Promising Pipeline and Strong Financial Position

TIPRANKS
·
06 Mar

iTeos Therapeutics Full Year 2024 Earnings: In Line With Expectations

Simply Wall St.
·
06 Mar

BUZZ-iTeos Therapeutics rises after reporting narrower-than-expected quarterly loss

Reuters
·
06 Mar

Iteos Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Iteos Therapeutics Inc expected to post a loss of $1.06 a share - Earnings Preview

Reuters
·
05 Mar

ITeos Therapeutics Q4 2024 GAAP EPS $(1.01) Beats $(1.06) Estimate, Cash Balance And Investment Balance Of $655M As Of December 31, 2024 Expected To Provide Runway Through 2027

Benzinga
·
05 Mar

Iteos Therapeutics Inc - Cash Balance of $655 Million Expected to Provide Runway Through 2027

THOMSON REUTERS
·
05 Mar

Iteos Therapeutics Inc Qtrly Net Loss of $1.01 per Basic and Diluted Share

THOMSON REUTERS
·
05 Mar

Iteos Therapeutics Inc Q4 Shr View $-1.06 -- Lseg Ibes Data

THOMSON REUTERS
·
05 Mar

Press Release: iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Dow Jones
·
05 Mar

iTeos Therapeutics Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Jan

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy

Zacks
·
14 Jan

iTeos Therapeutics Plans 2025 Data Presentation on Therapies

TIPRANKS
·
13 Jan